Eyepoint Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
EyePoint Pharmaceuticals reported a significant increase in net loss for Q3 2025 and the nine months ended September 30, 2025, driven by accelerated R&D for its lead candidate DURAVYU, while securing a $162.1 million equity financing to extend its cash runway into Q4 2027.
NASDAQ
EyePoint Pharmaceuticals reported a significant increase in net loss for Q2 2025 driven by higher research and development costs for its lead drug candidate DURAVYU, despite positive clinical trial progress.
NASDAQ
10-Q: EyePoint Pharmaceuticals Reports Q1 2025 Results, Driven by Royalty Income and DURAVYU Progress
EyePoint Pharmaceuticals' Q1 2025 results show increased revenue driven by royalty income, progress in DURAVYU clinical trials, and a net loss of $45.2 million.
NASDAQ
EyePoint Pharmaceuticals reported its Q3 2024 financial results, highlighted by increased R&D spending and progress in its DURAVYU clinical trials.
NASDAQ
EyePoint Pharmaceuticals reported its second quarter 2024 financial results, highlighting progress in clinical trials for DURAVYU and a shift in revenue streams following the sale of YUTIQ rights.
NASDAQ
EyePoint Pharmaceuticals saw a revenue increase in Q1 2024 primarily due to licensing agreements, while research and development expenses also significantly increased.